RCM-1

**RCM-1** is a nontoxic small molecule inhibitor of the transcription factor **Forkhead box M1 (FOXM1)**, identified through a high-throughput screen targeting goblet cell differentiation. It blocks FOXM1 nuclear localization (IC50 = 0.72 μM), promotes its ubiquitination and proteasomal degradation, and suppresses FOXM1 target genes like Plk1 and Cdc25B. In preclinical models, RCM-1 inhibits goblet cell metaplasia, excessive mucus production, airway hyperreactivity, and inflammation in response to allergens like house dust mite (HDM) or IL-13, while also demonstrating antitumor effects by reducing proliferation and increasing apoptosis in rhabdomyosarcoma, melanoma, and lung adenocarcinoma models, often synergizing with low-dose vincristine.[1][2][3][5]

Other names

RCM1RCM-1RCM 1